At a glance
Side-by-side comparison
| Metric |
CURE
Global X S&P Biotech ETF
|
DRUG
BetaShares Global Healthcare ETF - Currency Hedged
|
IXI
iShares Global Consumer Staples ETF
|
IXJ
iShares Global Healthcare ETF
|
|---|---|---|---|---|
| Snapshot | ||||
| Provider |
Global X
|
BetaShares
|
iShares
|
iShares
|
| Tracks index |
S&P Biotechnology Select Industry Index
|
Nasdaq Global ex-Australia Healthcare Hedged AUD Index
|
S&P Global 1200 Consumer Staples Sector Index
|
S&P Global 1200 Health Care Sector Index
|
| Categories |
US, Thematic
|
Intl, Thematic
|
Intl, Thematic, Market-Cap
|
Intl, Thematic, Market-Cap
|
| Listed since |
2021 (5 yrs)
|
—
|
2007 (19 yrs)
|
2007 (19 yrs)
|
| Fund size (AUM) |
$46m
|
$172m
|
$136m
|
$1.4bn
|
| Cost & income | ||||
| Management fee |
0.45%
|
0.57%
|
0.4%
|
0.4%
|
| Dividend yield |
0%
|
4%
|
2.01%
|
1.61%
|
| Franking |
0%
|
0%
|
0%
|
0%
|
| Turnover |
35%
|
—
|
5%
|
5%
|
| Tax drag | 0.84% | 1.28% | 0.76% | 0.64% |
| Returns |
Tax bracket
|
|||
| 1-year return |
57.4%
net
|
20.8%
net
|
1.5%
net
|
12.1%
net
|
| 3-year return |
18.5%
net
|
5.7%
net
|
4.5%
net
|
5.1%
net
|
| 5-year return |
4.3%
net
|
4.2%
net
|
5.4%
net
|
5.3%
net
|
| 10-year return |
—
|
—
|
6.3%
net
|
8.9%
net
|
| Risk | ||||
| Volatility (3y) |
25.5%
|
12.6%
|
9.4%
|
12.9%
|
| Volatility (5y) |
24.9%
|
13.2%
|
10.7%
|
12.4%
|
| Volatility (10y) |
—
|
—
|
10.6%
|
11.6%
|
| Sharpe ratio (3y) |
0.63
|
0.18
|
—
|
0.14
|
| Sharpe ratio (5y) |
0.16
|
0.13
|
0.24
|
0.22
|
| Sharpe ratio (10y) |
—
|
—
|
0.42
|
0.6
|
| Bid/ask spread |
—
|
—
|
—
|
—
|
marks the strongest fund in each row. “net” shows the after-tax return at your selected bracket. “—” means we don’t have that data point yet.
Each fund at a glance
- Top-2% returns over 1 year (7th of 308 ETFs we track).
- Cheaper alternatives exist: IXJ and IXI.
- Top-14% returns over 1 year (43rd of 308 ETFs we track).
- Pays a useful 4% income yield.
- Has lagged most peers over 3 years (169th of 226).
- Low-cost: a 0.4% management fee keeps more of the return in your pocket.
- Has lagged most peers over 3 years (182nd of 226).
- Low-cost: a 0.4% management fee keeps more of the return in your pocket.
- Has lagged most peers over 3 years (174th of 226).
Frequently Asked Questions
CURE, DRUG, IXI, and IXJ are 4 Australian-listed ETFs we compare side by side. IXI carries the lowest management fee (0.4%). Over 10 years, IXJ has delivered the highest total return (8.9% a year). The table above breaks down fees, returns, income and risk for each.
IXI has the lowest management fee at 0.4% a year, versus CURE 0.45%, DRUG 0.57%, and IXJ 0.4%.
Over the past 10 years, IXJ has delivered the highest total return at 8.9% a year. Past performance is not a reliable indicator of future returns.
DRUG pays the highest at 4%. Remember distributions are taxed each year at your marginal rate.
IXJ is the largest fund by assets ($1.4bn). Larger funds are typically more liquid and trade on tighter spreads.
Related comparisons
General information only, generated from each fund's published data — not personal financial advice. Past performance is not a reliable indicator of future returns. Consider your own circumstances or seek licensed advice before investing.